Glenmark Pharma Gets USFDA Nod for Fluticasone Nasal Spray

Glenmark Pharmaceuticals has successfully secured approval from the U.S. Food and Drug Administration (USFDA) for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. This significant regulatory clearance enables Glenmark Pharmaceuticals Inc., USA, to commence distribution of the product across the U.S. market, marking a key milestone in its American operations.

Specifics of the Approval

• The newly approved product is Fluticasone Propionate Nasal Spray USP, at a concentration of 0.05 mg/spray.
• It has been rigorously confirmed as bioequivalent and therapeutically equivalent to the reference listed drug.
• The reference drug is Flonase Nasal Spray, also 0.05 mg/spray, manufactured by Haleon US Holdings LLC, identified under NDA 020121.

This approval allows Glenmark to introduce a high-quality generic alternative into a well-established pharmaceutical segment. The move is set to enhance the availability of an important treatment option for consumers in the United States.

Market Dynamics and Sales Performance

The market segment targeted by Glenmark’s new approval demonstrates robust financial performance. According to comprehensive IQVIA sales data, the existing Flonase Nasal Spray market generates substantial annual revenue.

• The Flonase Nasal Spray market recorded annual sales totaling approximately $295.2 million.
• This impressive sales figure pertains to the comprehensive 12-month period concluding in June 2026.
• IQVIA sales data served as the authoritative source for these market performance metrics.

Glenmark Pharmaceuticals operates as a prominent global, research-led pharmaceutical company. Its expansive presence covers Generics, Specialty, and Over-The-Counter (OTC) businesses across a multitude of countries worldwide.

The USFDA approval further solidifies Glenmark’s strategic position in crucial global pharmaceutical markets. This development aligns with the company’s ongoing commitment to broadening its product offerings and strengthening its footprint within highly regulated healthcare landscapes.